world class talent with the mission to reshape ep acutus medical has attracted some of the most respected pioneers and leaders in electrophysiology and cardiac device manufacturing to join our organization and our worldwide network of collaborative partners. the common bond that brings us together is our passion and collective capability to revolutionize a field that has not seen major technological advances in decades. our mission of continual innovation is focused on providing electrophysiologists with the highest quality suite of tools, coupled with outstanding clinical and technical support, to better understand and effectively treat complex arrhythmias. electrophysiology is a high growth market with a clear need for a leap-frog technology to address the unmet need for a scientific, medical evidence-based approach to treating atrial fibrillation, ventricular tachycardia and the other complex arrhythmia's. acutus medical is a full-portfolio solution provider for treating these patie
Company profile
Ticker
AFIB
Exchange
Website
CEO
Vince Burgess
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Acutus Medical, N.V. • Acutus Medical UK Limited ...
IRS number
451306615
AFIB stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Acutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results
1 Apr 24
8-K
Entry into a Material Definitive Agreement
4 Mar 24
8-K
Termination of a Material Definitive Agreement
8 Feb 24
8-K
Departure of Directors or Certain Officers
17 Jan 24
8-K
Departure of Directors or Certain Officers
11 Jan 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
Transcripts
AFIB
Earnings call transcript
2023 Q2
7 Aug 23
AFIB
Earnings call transcript
2023 Q1
11 May 23
AFIB
Earnings call transcript
2022 Q4
17 Mar 23
AFIB
Earnings call transcript
2022 Q3
13 Nov 22
AFIB
Earnings call transcript
2022 Q2
12 Aug 22
AFIB
Earnings call transcript
2022 Q2
13 May 22
AFIB
Earnings call transcript
2021 Q4
31 Mar 22
AFIB
Earnings call transcript
2021 Q3
12 Nov 21
AFIB
Earnings call transcript
2021 Q2
13 Aug 21
AFIB
Earnings call transcript
2021 Q1
13 May 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 31.12 mm | 31.12 mm | 31.12 mm | 31.12 mm | 31.12 mm | 31.12 mm |
Cash burn (monthly) | (no burn) | 86.50 k | 4.39 mm | 2.67 mm | 4.67 mm | 4.84 mm |
Cash used (since last report) | n/a | 596.47 k | 30.25 mm | 18.38 mm | 32.20 mm | 33.38 mm |
Cash remaining | n/a | 30.52 mm | 861.72 k | 12.73 mm | -1.08 mm | -2.26 mm |
Runway (months of cash) | n/a | 352.8 | 0.2 | 4.8 | -0.2 | -0.5 |
Institutional ownership, Q2 2023
72.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 38 |
Opened positions | 4 |
Closed positions | 6 |
Increased positions | 9 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 7.58 bn |
Total shares | 21.58 mm |
Total puts | 100.00 |
Total calls | 22.50 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 9.64 mm | $10.80 mm |
Deerfield Management | 2.66 mm | $2.36 bn |
Orbimed Advisors | 2.65 mm | $2.35 bn |
Advent Life Sciences | 1.62 mm | $5.51 mm |
Fares Zahir | 1.17 mm | $33.61 mm |
Vanguard | 1.14 mm | $1.01 bn |
Parkman Healthcare Partners | 762.03 k | $676.68 mm |
Renaissance Technologies | 369.90 k | $328.00 k |
AFG American Financial | 300.00 k | $266.00 k |
BLK Blackrock | 226.30 k | $200.95 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Takeo Mukai | Form 4 | Payment of exercise | Dispose F | No | No | 0.21 | 8,475 | 1.78 k | 72,874 |
6 Feb 24 | Tom Sohn | Form 4 | Payment of exercise | Dispose F | No | No | 0.173 | 7,582 | 1.31 k | 105,009 |
7 Jan 24 | David Roman | Form 4 | Payment of exercise | Dispose F | No | No | 0.189 | 24,086 | 4.55 k | 332,134 |
7 Jan 24 | Kevin Mathews | Form 4 | Payment of exercise | Dispose F | No | No | 0.189 | 6,342 | 1.20 k | 61,106 |
1 Sep 23 | Takeo Mukai | FORM 4 | Payment of exercise | Dispose F | No | No | 0.488 | 1,729 | 843.75 | 84,218 |
News
Earlier Announced, Acutus Medical Was Granted EU Patent #3294412 For "Localization System And Method Useful In The Acquisition And Analysis Of Cardiac Information".
18 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
17 Apr 24
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
19 Mar 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
19 Mar 24
Why Fusion Pharmaceuticals Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket
19 Mar 24